Cargando…
Challenges in nonparenteral nanomedicine therapy
The application of nanotechnology for medical purposes has been defined as nanomedicine and is specifically focused on the use of nanomaterials for diagnosis, imaging, management, prevention, and treatment of diseases. These medical necessities greatly increase a set of opportunities in drug develop...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499062/ http://dx.doi.org/10.1016/B978-0-12-820466-5.00002-8 |
_version_ | 1783583642459570176 |
---|---|
author | G., Praveen Kalarikkal, Nandakumar Thomas, Sabu |
author_facet | G., Praveen Kalarikkal, Nandakumar Thomas, Sabu |
author_sort | G., Praveen |
collection | PubMed |
description | The application of nanotechnology for medical purposes has been defined as nanomedicine and is specifically focused on the use of nanomaterials for diagnosis, imaging, management, prevention, and treatment of diseases. These medical necessities greatly increase a set of opportunities in drug development; however, some concerns about safety issues have emerged. In comparison, the physicochemical and pharmacokinetic properties of the nanoformulation can largely differ with its parent drug molecule, especially in the rates of absorption, distribution, elimination, and metabolism. It is also proven that such miniaturized drug formulations have greater potential to cross biological barriers. Greater concerns are also there about toxic properties of such synthesized nano-formulations and their persistence in the environment and the human body. In this chapter, it is aimed to elucidate the critical challenges faced by the researchers and clinicians during the development and usage of such nano-formulations especially when administered through nonparenteral routes. The topics outlined in this chapter addresses critical concerns regarding the complexity of the nonparental nanomedicines and provide basic information about the pharmaceutical development, its nonclinical, and early clinical studies. |
format | Online Article Text |
id | pubmed-7499062 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-74990622020-09-18 Challenges in nonparenteral nanomedicine therapy G., Praveen Kalarikkal, Nandakumar Thomas, Sabu Theory and Applications of Nonparenteral Nanomedicines Article The application of nanotechnology for medical purposes has been defined as nanomedicine and is specifically focused on the use of nanomaterials for diagnosis, imaging, management, prevention, and treatment of diseases. These medical necessities greatly increase a set of opportunities in drug development; however, some concerns about safety issues have emerged. In comparison, the physicochemical and pharmacokinetic properties of the nanoformulation can largely differ with its parent drug molecule, especially in the rates of absorption, distribution, elimination, and metabolism. It is also proven that such miniaturized drug formulations have greater potential to cross biological barriers. Greater concerns are also there about toxic properties of such synthesized nano-formulations and their persistence in the environment and the human body. In this chapter, it is aimed to elucidate the critical challenges faced by the researchers and clinicians during the development and usage of such nano-formulations especially when administered through nonparenteral routes. The topics outlined in this chapter addresses critical concerns regarding the complexity of the nonparental nanomedicines and provide basic information about the pharmaceutical development, its nonclinical, and early clinical studies. 2021 2020-09-18 /pmc/articles/PMC7499062/ http://dx.doi.org/10.1016/B978-0-12-820466-5.00002-8 Text en Copyright © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article G., Praveen Kalarikkal, Nandakumar Thomas, Sabu Challenges in nonparenteral nanomedicine therapy |
title | Challenges in nonparenteral nanomedicine therapy |
title_full | Challenges in nonparenteral nanomedicine therapy |
title_fullStr | Challenges in nonparenteral nanomedicine therapy |
title_full_unstemmed | Challenges in nonparenteral nanomedicine therapy |
title_short | Challenges in nonparenteral nanomedicine therapy |
title_sort | challenges in nonparenteral nanomedicine therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499062/ http://dx.doi.org/10.1016/B978-0-12-820466-5.00002-8 |
work_keys_str_mv | AT gpraveen challengesinnonparenteralnanomedicinetherapy AT kalarikkalnandakumar challengesinnonparenteralnanomedicinetherapy AT thomassabu challengesinnonparenteralnanomedicinetherapy |